Survey Results

Page: Demographic data

1. Your pseudonym (unique identifier)
	answered question	1,547
	skipped question	2
		Response Count
[ShowReplies]		1,547

2. Patient identifier (must be unique)
	answered question	1,547
	skipped question	2
		Response Count
[ShowReplies]		1,547

Page: Diagnosis

3. Was this patient diagnosed with MDS?
	answered question		1,512
	skipped question		37
		Response Percent	Response Count
Yes		99.7%	1,507
No		0.3%	5

Page: Diagnostic Testing

4. Did this patient's diagnostic evaluation include cytogenetic testing on bone marrow within 12 weeks of diagnosis? (Measure 1)
	answered question		1,478
	skipped question		71
		Response Percent	Response Count
Yes		92.4%	1,365
No		7.0%	104
Other (please specify) [ShowReplies]		0.9%	13

5. Did you use an established risk classification/prognostication system to help plan your patient's treatment? (Measure 2)
	answered question		1,478
	skipped question		71
		Response Percent	Response Count
Yes		85.9%	1,269
No		14.1%	209

Page: Risk classification/prognostication

6. Which established risk classification/prognostication system did you use?
	answered question		1,261
	skipped question		288
		Response Percent	Response Count
IPSS (International Prognostic Scoring System)		72.5%	914
WHO (World Health Organization)		11.4%	144
Other (please specify) [ShowReplies]		0.2%	3

Page: Erythropoietin/Darbepoietin

7. Has this MDS patient ever received erythropoietin/darbepoietin?
	answered question		1,465
	skipped question		84
		Response Percent	Response Count
Yes		65.1%	954
No		35.2%	516

Page: Erythropoietin/Darbepoietin Therapy

8. Did your patient have anemia before treatment started?
	answered question		956
	skipped question		593
		Response Percent	Response Count
Yes		98.0%	937
No		1.4%	13
Other (please specify) [ShowReplies]		0.6%	6

9. Did you determine that your patient had adequate iron stores for treating MDS with erythropoietin/darbepoietin? Adequate iron stores is determined by EITHER bone marrow examination, including iron stain OR peripheral blood iron showing ferritin >100 ng/ml and/or the ratio of serum iron to TIBC >20%. (Measure 3)
	answered question		956
	skipped question		593
		Response Percent	Response Count
Yes		95.9%	917
No		3.2%	31
Other (please specify) [ShowReplies]		0.9%	9

10. Was this patient's serum erythropoietin level <=500 mU/ml prior to starting erythropoietin/darbepoietin therapy? (Measure 4)
	answered question		956
	skipped question		593
		Response Percent	Response Count
Yes		65.9%	630
No		16.0%	153
Other (please specify) [ShowReplies]		18.5%	177

11. Did you evaluate response of the hemoglobin to erythropoietin/darbepoietin therapy after 8 weeks of maximal therapy and adjust your prescription? Adjust your prescription means discontinued erythropoietin/darbepoietin therapy in the absence of benefit, or decreased dose to tolerance if positive response.
	answered question		956
	skipped question		593
		Response Percent	Response Count
Yes		92.5%	884
No		3.3%	32
Other (please specify) [ShowReplies]		4.3%	41

Page: Response to erythropoietin/darbepoietin

12. Did this patient have a positive response to erythropoietin/darbepoietin therapy after 8 weeks?
	answered question		922
	skipped question		627
		Response Percent	Response Count
Yes		71.0%	655
No		29.4%	271

Page: Positive response to erythropoietin/darbepoeitin therapy

13. Did you decrease dose to tolerance? (Measure 5A)
	answered question		662
	skipped question		887
		Response Percent	Response Count
Yes		78.9%	522
No		16.5%	109
Other (please specify) [ShowReplies]		4.7%	31

Page: Absence of benefit to erythropoietin/darbepoietin therapy

14. Did you discontinue erythropoietin/darbepoietin in the absence of benefit? (Measure 5B)
	answered question		283
	skipped question		1,266
		Response Percent	Response Count
Yes		79.9%	226
No		10.6%	30
Other (please specify) [ShowReplies]		9.9%	28

Page: Transfusional Hemosiderosis

15. Has this MDS patient had more than 20 units of packed red cells transfused OR a ferritin level >1000 ng/ml?
	answered question		1,445
	skipped question		104
		Response Percent	Response Count
Yes		24.3%	351
No		76.0%	1,098

Page: Chelation Therapy

16. Did you start this patient on intravenous or oral iron chelation therapy to decrease iron overload? (Measure 6)
	answered question		365
	skipped question		1,184
		Response Percent	Response Count
Yes		54.0%	197
No		41.1%	150
Other (please specify) [ShowReplies]		5.2%	19

Page: Stem Cell Candidate

17. Is this patient is a candidate for allogeneic stem cell transplantation?
	answered question		1,444
	skipped question		105
		Response Percent	Response Count
Yes		17.9%	258
No		82.3%	1,188

Page: Irradiated Transfusion Products

18. Are you ordering irradiated transfusion products? (Measure 7)
	answered question		263
	skipped question		1,286
		Response Percent	Response Count
Yes		87.8%	231
No		8.0%	21
Other (please specify) [ShowReplies]		4.2%	11

Page: Clinical Trials

19. Has this patient been checked for clinical trial eligibility in the past year? (Measure 8)
	answered question		1,438
	skipped question		111
		Response Percent	Response Count
Yes		45.5%	655
No		51.2%	736
Other (please specify) [ShowReplies]		3.5%	50